254 related articles for article (PubMed ID: 34414880)
1. Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021.
Lee E; Lee YK; Kim TE; Hwang I; Jung YH; Lee HR; Song J; Park Y; Cho E; Lee YK
Euro Surveill; 2021 Aug; 26(33):. PubMed ID: 34414880
[TBL] [Abstract][Full Text] [Related]
2. Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID-19 vaccinations, Western Australia, 22 February to 30 June 2021.
Shivarev A; Phillips A; Brophy-Williams S; Ford T; Richmond P; Effler P; McLean-Tooke A
Intern Med J; 2023 Feb; 53(2):275-279. PubMed ID: 36585764
[TBL] [Abstract][Full Text] [Related]
3. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021.
Hwang I; Park K; Kim TE; Kwon Y; Lee YK
Osong Public Health Res Perspect; 2021 Dec; 12(6):396-402. PubMed ID: 34965689
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-related Anaphylaxis Cases Confirmed by KCDC from 2001-2016.
Roh EJ; Lee MH; Song KB; Lee YK; Kim MK; Kim TE; Chung EH
J Korean Med Sci; 2020 Sep; 35(38):e337. PubMed ID: 32989932
[TBL] [Abstract][Full Text] [Related]
6. Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.
Almohaya AM; Alsubie H; Alqarni B; Alzayad B; Alghar A; Alshahrani K; Barry M
Vaccine; 2022 Jan; 40(3):477-482. PubMed ID: 34916104
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
[TBL] [Abstract][Full Text] [Related]
8. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.
Tavares F; Delaigle A; Slavin D; Bauchau V; Fries L; Seifert H
Vaccine; 2011 Aug; 29(37):6402-7. PubMed ID: 21527305
[TBL] [Abstract][Full Text] [Related]
9. Anaphylaxis: Revision of the Brighton collaboration case definition.
Gold MS; Amarasinghe A; Greenhawt M; Kelso JM; Kochhar S; Yu-Hor Thong B; Top KA; Turner PJ; Worm M; Law B
Vaccine; 2023 Apr; 41(15):2605-2614. PubMed ID: 36435707
[TBL] [Abstract][Full Text] [Related]
10. An algorithm developed using the Brighton Collaboration case definitions is more efficient for determining diagnostic certainty.
Joshi D; Alsentzer E; Edwards K; Norton A; Williams SE
Vaccine; 2014 Jun; 32(28):3469-72. PubMed ID: 24795227
[TBL] [Abstract][Full Text] [Related]
11. Estimating Baseline Incidence of Conditions Potentially Associated with Vaccine Adverse Events: a Call for Surveillance System Using the Korean National Health Insurance Claims Data.
Huh K; Kim YE; Radnaabaatar M; Lee DH; Kim DW; Shin SA; Jung J
J Korean Med Sci; 2021 Mar; 36(9):e67. PubMed ID: 33686812
[TBL] [Abstract][Full Text] [Related]
12. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies.
Shaker M; Abrams EM; Greenhawt M
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2658-2668.e3. PubMed ID: 33711496
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021.
Oh HK; Kim EK; Hwang I; Kim TE; Lee YK; Lee E; Lee YK
Osong Public Health Res Perspect; 2021 Aug; 12(4):264-268. PubMed ID: 34465075
[TBL] [Abstract][Full Text] [Related]
14. Delay-Adjusted Age-Specific COVID-19 Case Fatality Rates in a High Testing Setting: South Korea, February 2020 to February 2021.
Shim E
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064703
[TBL] [Abstract][Full Text] [Related]
15. Risk of anaphylaxis after vaccination in children and adults.
McNeil MM; Weintraub ES; Duffy J; Sukumaran L; Jacobsen SJ; Klein NP; Hambidge SJ; Lee GM; Jackson LA; Irving SA; King JP; Kharbanda EO; Bednarczyk RA; DeStefano F
J Allergy Clin Immunol; 2016 Mar; 137(3):868-78. PubMed ID: 26452420
[TBL] [Abstract][Full Text] [Related]
16. Management of patients at risk of anaphylaxis after COVID 19 vaccination.
Gangemi S; Allegra A; Di Gioacchino M
J Biol Regul Homeost Agents; 2021; 35(3):843-846. PubMed ID: 34231348
[TBL] [Abstract][Full Text] [Related]
17. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
[TBL] [Abstract][Full Text] [Related]
18. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
;
MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(4):125-129. PubMed ID: 33507892
[TBL] [Abstract][Full Text] [Related]
19. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016.
Su JR; Moro PL; Ng CS; Lewis PW; Said MA; Cano MV
J Allergy Clin Immunol; 2019 Apr; 143(4):1465-1473. PubMed ID: 30654049
[TBL] [Abstract][Full Text] [Related]
20. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
